Reading the tape
NASDAQ: KRYS
Krystal Biotech, Inc.
Healthcare · Biotechnology
Market Cap
$8.40B
52w High
$303.00
52w Low
$122.80
P/E
37.16
Volume
265.33K
Outstanding Shares
29.44M
Price vs Fundamentals
Why The Stock Is Moving
Fundamentals are supporting the moveHigh confidence
1Y Price: 76.34%Revenue (TTM): 25.15%FCF (TTM): 83.56%P/E: 40th pct
What changed
The stock rose 76.34% over the last year. Revenue grew 25.15% over the trailing twelve months. Operating margin moved from 32.56% to 42.85%. Free cash flow grew 83.56% over the trailing twelve months.
What the market seems to be pricing
The stock move broadly lines up with stronger business momentum, and the shares are still only around the 40th percentile of their historical P/E range.
What would invalidate this read
Operating margin is at 42.85%. Revenue grew 25.15% — this thesis depends on that trajectory holding. If revenue growth, margins, or free cash flow roll over while the stock keeps climbing, more of the move would be coming from multiple expansion than business progress.
Company profile
Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States.
CEOKrish S. Krishnan
SectorHealthcare
IndustryBiotechnology
Employees275
IPO dateSep 20, 2017
Valuation
Forward P/E—
EV/EBITDA39.61
Enterprise value$6.65B
Stock splits
No stock splits recorded for this ticker.
Profitability & growth
Revenue growth31.95%
Gross margin92.79%▼0.53%vs FY2024
Operating margin42.85%▲83.30%vs FY2024
ROE16.8%▲78.28%vs FY2024
Analyst consensus
RatingBuy
Target price$326.20▲14.25%
17
Buy
0
Hold
0
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
Aug 3, 2026
Q3 FY26 · EPS est $1.73 · Revenue est $124.69M
View